Focus Reports by Arizton’s Post

❓Fecal incontinence is a condition that is hugely prevalent, yet underreported and stigmatized. 📄 In this article, together with colleagues from ttopstart and the AMELIE project, we hoped to raise awareness and highlight the potential of cell therapy as a potential alternative to the current therapeutic options. 👉🏼To read the full article, you can follow the link in the post below.

The article I wrote in collaboration with my colleagues from ttopstart and the AMELIE consortium is now published in Cell & Gene Therapy Insights! Here we discuss how regenerative medicine can be used to treat faecal incontinence.

📄 New whitepaper in the Journal of Cell and Gene Therapy Insights highlights the overlooked burden of faecal incontinence (FI) and proposes cell therapy as a transformative solution. The paper discusses the potential of cell therapy to provide a minimally invasive, curative option compared to current treatments. The AMELIE project, supported by CVBF, is a notable initiative in this field. For more details, access the open-access paper. #CellTherapy #MedicalResearch #FaecalIncontinence #AMELIE 

How can the latest cell therapy technologies be harnessed to treat faecal incontinence? Read our newly published article, free to read in the Cell and Gene Therapy Insights journal: https://lnkd.in/ee_aNQYp #faecalincontinence #regenerativemedicine #celltherapy

Are you visiting the Cell and Gene Therapy Pricing and Reimbursement Summit in Washington DC? Hear from Tom Smith on Wednesday June 26, at 11.15am. Tom will be discussing how Uniphar are accelerating global patient access to cell and gene therapies. #CellandGeneTherapy #PricingReimbursement #MarketAccess #ExpandedAccess

Driven by a continued focus on personalised medicine, cell and gene therapies have experienced continued growth over the past 15 years, with the number of FDA-approved therapies more than doubling since 2020. Andrew Way from our Life Sciences team explores the main challenges associated with the rise of new therapies entering the market and how these might be tackled. Read blog > https://lnkd.in/e7EA3jN6 #mrx #lifescience #healthresearch

"Recent years have seen a translational evolution in #genetherapy from state-of-the-art sciences to #patient care. With the marketing approval of Hemgenix, an adeno-associated virus vector-based gene #therapy for the treatment of adults with Hemophilia B, it heralds of a new age of gene therapy." As gene therapies continue to evolve, KCR Chief Medical Officer, Dr. Anna Baran and Principal Consultant, Dave Li, explain how they arrived to the market and the challenges that still lie ahead. Check it out! #KCRCRO #ClinicalTrials #ClinicalResearch #Innovation #WhitePaper #GeneTherapy

Given the complexity and costs associated with cell and gene therapy trials, you need a clinical research partner who can help you navigate challenges and make sure your trial runs smoothly. Read our white paper to learn more about the importance of strategic alliances for cell & gene therapy trials: https://hubs.la/Q02DTzT-0 #CellandGeneTherapy #CellTherapy #GeneTherapy #ClinicalTrials #ClinicalResearch

🚀Check out our new Gene Therapy RESEARCH Portfolio! - #AAV Reference Materials - #LVV Reference Materials - AAV and LVV Plasmids - #ViralVector Packaging Services - Custom Cloning - Molecular Cloning - Gene Synthesis and Mutagenesis - shRNA Cloning #genetherapy #research

Exciting developments in the world of gene therapies! The U.K. is pioneering academia-led initiatives to accelerate innovation in this field. The Innovation Hubs for Gene Therapies are now operational, offering cutting-edge manufacturing services to academic researchers. With a focus on rare diseases, these facilities aim to bridge the gap between academia and commercialization. Learn more about this groundbreaking initiative and its potential to drive advancements in gene therapy research and development. #GeneTherapies #AcademiaInnovation